Cargando…

Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer’s Disease

BACKGROUND: Quality of Life (QoL) is an important outcome measure in dementia, particularly in the context of interventions. Research investigating longitudinal QoL in dementia with Lewy bodies (DLB) is currently lacking. OBJECTIVE: To investigate determinants and trajectories of QoL in DLB compared...

Descripción completa

Detalles Bibliográficos
Autores principales:	van de Beek, Marleen, van Steenoven, Inger, Ramakers, Inez H.G.B., Aalten, Pauline, Koek, Huiberdina L., Olde Rikkert, Marcel G.M., Manniën, Judith, Papma, Janne M., de Jong, Frank Jan, Lemstra, Afina W., van der Flier, Wiesje M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839497/ https://www.ncbi.nlm.nih.gov/pubmed/31177218 http://dx.doi.org/10.3233/JAD-190041

Ejemplares similares

Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression
por: van de Beek, Marleen, et al.
Publicado: (2020)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Disease progression in dementia with Lewy bodies: A longitudinal study on clinical symptoms, quality of life and functional impairment
por: van de Beek, Marleen, et al.
Publicado: (2022)

Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer’s Disease
por: Geijselaers, Stefan L.C., et al.
Publicado: (2017)

Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies
por: van der Lee, Sven J., et al.
Publicado: (2021)

VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson’s Disease Patients and Is Present within Lewy Bodies
por: Chatterjee, Madhurima, et al.
Publicado: (2020)

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2018)

The Dutch Parelsnoer Institute - Neurodegenerative diseases; methods, design and baseline results
por: Aalten, Pauline, et al.
Publicado: (2014)

Family History is Associated with Phenotype in Dementia with Lewy Bodies
por: Vergouw, Leonie J.M., et al.
Publicado: (2020)

EEG Characteristics of Dementia With Lewy Bodies, Alzheimer’s Disease and Mixed Pathology
por: van der Zande, Jessica J., et al.
Publicado: (2018)

Optimizing cCOG, a Web‐based tool, to detect dementia with Lewy Bodies
por: van Gils, Aniek M., et al.
Publicado: (2022)

Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies
por: van de Beek, M., et al.
Publicado: (2020)

Cognitive and functional progression of dementia in two longitudinal studies
por: Wang, Yuwei, et al.
Publicado: (2019)

Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies
por: Rossi, Marcello, et al.
Publicado: (2021)

Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach
por: van Steenoven, Inger, et al.
Publicado: (2020)

Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results
por: van de Beek, M., et al.
Publicado: (2021)

Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer’s disease
por: Bron, Esther E., et al.
Publicado: (2021)

A comparison of two approaches for modeling dementia progression in a changing patient context
por: Wubben, Nina, et al.
Publicado: (2022)

Performance of a [(18)F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies
por: Coomans, Emma M., et al.
Publicado: (2023)

Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline
por: Bos, Isabelle, et al.
Publicado: (2017)

Development of memory clinics in the Netherlands over the last 20 years
por: Gruters, Angélique A.A., et al.
Publicado: (2019)

MRI data-driven clustering reveals different subtypes of Dementia with Lewy bodies
por: Inguanzo, Anna, et al.
Publicado: (2023)

A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands
por: Liao, Weiqi, et al.
Publicado: (2016)

CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease
por: del Campo, Marta, et al.
Publicado: (2023)

Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data
por: Abdelnour, Carla, et al.
Publicado: (2022)

Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease
por: Dauwan, Meenakshi, et al.
Publicado: (2016)

Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF
por: Boiten, Walter A., et al.
Publicado: (2020)

Correction: Boiten et al. Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF. Cells 2021, 10, 38
por: Boiten, Walter A., et al.
Publicado: (2022)

Diagnosis and Care Use for People with Young-Onset Dementia in Primary Care in the Netherlands
por: Hendriks, Stevie, et al.
Publicado: (2023)

Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline
por: Bos, Isabelle, et al.
Publicado: (2018)

Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer’s disease
por: Hok-A-Hin, Yanaika S., et al.
Publicado: (2023)

Orthostatic Hypotension: An Important Risk Factor for Clinical Progression to Mild Cognitive Impairment or Dementia. The Amsterdam Dementia Cohort
por: Kleipool, Emma E.F., et al.
Publicado: (2019)

Disease-related determinants are associated with mortality in dementia due to Alzheimer’s disease
por: Rhodius-Meester, Hanneke F. M., et al.
Publicado: (2018)

Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice
por: Vos, Stephanie J. B., et al.
Publicado: (2014)

Survival in memory clinic cohort is short, even in young-onset dementia
por: Rhodius-Meester, Hanneke Frederica Maria, et al.
Publicado: (2019)

Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study
por: Wolters, E.E., et al.
Publicado: (2020)

Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross‐platform validation study
por: Hok‐A‐Hin, Yanaika S., et al.
Publicado: (2023)

A Scoping Review of Communicating Neuropsychological Test Results to Patients and Family Members
por: Gruters, Angélique AA, et al.
Publicado: (2021)

Psychosocial Effects of Corona Measures on Patients With Dementia, Mild Cognitive Impairment and Subjective Cognitive Decline
por: van Maurik, Ingrid S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_19b3roauqh2196ln6mh5h3c235